European Hornet VIT: The Only True Vespa in North America
European hornet (Vespa crabro) is the sole true Vespa species established in continental North America — yellow hornet and white-faced hornet, despite their names, are Dolichovespula. No FDA-standardized V. crabro venom extract exists in the US, so allergists treat Vespa crabro allergy using FDA-licensed Vespula (yellow jacket) VIT, exploiting 50–95% Vesp c 5 / Ves v 5 Antigen 5 cross-reactivity endorsed by the EAACI 2018 guidelines (Sturm 2018 Allergy 73:744).
European Hornet Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to european hornet — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of european hornet allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of european hornet immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of european hornet extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for european hornet allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing european hornet extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription european hornet immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat european hornet allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is European Hornet?
The biology, taxonomy, and clinical fingerprint of European Hornet — the foundation of how SCIT targets it.
Vespa crabro — the European hornet and the only true Vespa species established in continental North America; builds aerial nests in hollow trees, attics, and barns and may be attracted to outdoor lighting.
- Scientific name
- Vespa crabro
- Family
- VespidaeWasp and hornet family
- Type
- Hymenoptera venom (true Vespa hornet; smooth retractable stinger; large body 25–35 mm)
- Native to
- Europe and Asia; introduced to eastern US in the 1840s; now established across the eastern US from Maine to Georgia, west to the Mississippi Valley and Great Lakes
- Allergen proteins
- Vesp c 1 — Phospholipase A1 (34 kDa; major allergen)Vesp c 5 — Antigen 5 (23 kDa; major allergen; 50–95% cross-reactivity with Ves v 5 of yellow jacket)Vesp c 2 — Hyaluronidase (described but not yet IUIS-named; Hoffman 1985 JACI 75:611)
- Particle size
- N/A (venom protein, not pollen)
- Avoidance difficulty
- Moderate
How European Hornet Allergy Presents
Symptoms by body system — useful for distinguishing European Hornet sensitivity from overlapping allergies and infections.
Systemic (Anaphylaxis)
- Generalized urticaria and flushing within minutes of sting
- Throat tightness and difficulty breathing
- Hypotension and cardiovascular collapse in severe cases
- Loss of consciousness in the most severe reactions
- Nausea, vomiting, and abdominal cramping
Local / Dermal
- Significant local pain from the large body's relatively large venom volume
- Large local reaction >10 cm at sting site
- Pruritis and induration
Respiratory (in systemic reaction)
- Bronchospasm and wheezing
- Laryngeal edema producing stridor
- Upper airway obstruction requiring urgent epinephrine
Ocular
- Periorbital angioedema
- Conjunctival injection and tearing
- Eyelid swelling with nearby sting
European hornet is the only true hornet in North America — yellow hornet and bald-faced hornet are actually Dolichovespula. In the US we don't have an FDA-approved Vespa crabro venom, so we treat with Vespula extracts and rely on the 50 to 95 percent Antigen 5 cross-reactivity. EAACI accepts this approach; in Europe they have a dedicated V. crabro extract that some clinicians prefer when cross-reactivity testing comes back primary V. crabro.
When & Where European Hornet Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: August through October; crepuscular/nocturnal foraging may attract V. crabro to outdoor lighting after dark· ~4 months of meaningful sting risk in the eastern US
US Exposure Map
9 high-intensity statesWhat European Hornet Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
European hornet's Vesp c 5 Antigen 5 shares 50–95% cross-reactivity with Vespula yellow jacket — the basis for the EAACI-endorsed approach of using FDA-licensed Vespula VIT in US V. crabro–allergic patients.
Vesp c 5 ↔ Ves v 5 Antigen 5, 50–95% cross-reactivity; basis for FDA-licensed Vespula VIT in US V. crabro–allergic patients per EAACI Sturm 2018 Allergy 73:744
Is SCIT Right for Your European Hornet Allergy?
Answer 5 questions to assess your VIT candidacy for European hornet allergy and whether Vespula VIT (the US standard approach) may be appropriate.
How severe was your reaction to a European hornet sting?
The European Hornet SCIT Protocol
Because V. crabro venom is not FDA-licensed in the US, European hornet allergy is treated with FDA-licensed Vespula single-venom or mixed-vespid VIT, exploiting the Vesp c 5 / Ves v 5 Antigen 5 cross-reactivity per EAACI Sturm 2018 Allergy 73:744.
The allergist escalates the FDA-licensed Vespula single-venom or mixed-vespid extract toward the 100 μg or 300 μg maintenance target, with a mandatory 30-minute observation period after every injection. Component testing (rVes v 1, rVes v 5, and where available Vesp c components) confirms the adequacy of cross-reactivity-based protection versus primary V. crabro sensitization. In Europe, dedicated V. crabro extracts are available and may be used when primary V. crabro sensitization is confirmed on component testing.
Standard maintenance is 100 μg single Vespula venom or 300 μg total mixed-vespid. EAACI guidelines (Sturm 2018) accept Vespula VIT as protective against V. crabro in cross-reactive patients. Inhibition studies in Germany and Slovenia suggest 50–70% of apparent V. crabro anaphylaxis patients are actually primarily sensitized to Vespula (Korošec 2002 Croat Med J 43:25; Macchia 2018 World Allergy Organ J 11:3). Patients with true primary V. crabro sensitization and access to European medical care may be referred for dedicated Vesp c extract treatment abroad.
After completing a full VIT course, most patients achieve lasting re-sting tolerance via Antigen 5 cross-protection. Lifelong VIT is indicated for mast cell disorder, prior near-fatal anaphylaxis, or systemic reaction during VIT (Golden 2017; Sturm 2018).
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for European Hornet SCIT
European hornet VIT efficacy in the US extrapolates from the Vespula VIT evidence base via Antigen 5 cross-reactivity; no V. crabro–specific US RCT data exists, though European case series support the cross-reactive Vespula VIT approach (Macchia 2018 World Allergy Organ J 11:3).
- Vespid VIT efficacy (Vespula as the US cross-reactive surrogate for V. crabro)97%Müller 1992, JACI 89:529 — vespid VIT 95–98% re-sting protection
- Re-sting systemic reaction risk reduction (VIT vs untreated across Hymenoptera)90%Boyle 2012, Cochrane CD008838 — RR 0.10 (2.7% VIT vs 39.8% untreated)
- Proportion of apparent V. crabro reactions explained by primary Vespula sensitization60%Korošec 2002, Croat Med J 43:25 — inhibition studies: 50–70% of apparent V. crabro anaphylaxis patients primarily sensitized to Vespula
Vespula VIT provides evidence-based protection for most European hornet–allergic patients via Antigen 5 cross-reactivity, per EAACI guidelines (Sturm 2018 Allergy 73:744). For the minority of patients with confirmed primary V. crabro sensitization on component testing, dedicated European V. crabro extract may be superior — but it is not available in the US.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
European Hornet SCIT Side Effects
European hornet VIT in the US uses Vespula extract and carries the standard vespid safety profile — systemic reactions during build-up approximately 2%, large local reactions 30–50%.
Local reactions
3 documentedSystemic reactions
3 documentedAll VIT injections are venom immunotherapy and must be administered in an allergist's office with on-site epinephrine and a mandatory 30-minute post-injection observation period; venom immunotherapy should never be self-administered at home. Mast cell disorder workup (baseline tryptase) is recommended for severe V. crabro reactors, consistent with general Hymenoptera VIT framework. (This in-clinic requirement applies to venom immunotherapy only and is separate from the at-home aeroallergen shots Curex offers for coexisting inhalant allergies.)
SCIT vs Alternatives for European Hornet
European hornet allergy management in the US is governed primarily by the Vespula VIT cross-reactivity approach, avoidance of nocturnal outdoor lighting exposure, and epinephrine rescue for breakthrough encounters.
| Criterion | VIT (Vespula cross-react.)Best | Avoidance Only | Epinephrine Rescue | Antihistamines |
|---|---|---|---|---|
| Effectiveness | 95–98% via Vespula Ag5 cross-reactivity for most patients (Müller 1992) | Reduces exposure; counsel on outdoor lighting and hollow-tree nests | Rescue treatment; does not prevent anaphylaxis | Do not prevent European hornet anaphylaxis |
| 5-yr cost | $2,000–$8,000 over 3–5 yr | Cost of auto-injectors only | $300–$600/yr auto-injector refills | Low cost |
| Duration | 3–5 yrs (lifelong if mast cell dx) | Ongoing indefinitely | Ongoing; not curative | Daily ongoing |
| Convenience | Weekly clinic visits build-up; monthly maintenance | No clinic visits; requires night-time vigilance outdoors | Must carry at all times | Oral, convenient |
| Safety profile | ~2% systemic reactions during build-up | Safe if not stung; ~60% systemic-reaction risk on re-sting | Bridge to emergency care; risk of delay | Safe; ineffective for venom anaphylaxis |
| Lasting effect | Durable re-sting tolerance after full course | No immunologic change | No desensitization | No lasting effect |
VIT (Vespula cross-react.)Best
Avoidance Only
Epinephrine Rescue
Antihistamines
Vespula VIT is the US standard for European hornet allergy, providing cross-reactivity–based protection endorsed by EAACI 2018. For patients with concurrent inhalant allergies — dust mite, cat, dog, or seasonal pollen — Curex delivers those aeroallergens as at-home allergy shots at $129/month: a USP <797> sterile-compounded serum, the first injection and every dose increase walked through live over video by your care team, and a prescribed epinephrine auto-injector confirmed on hand. That at-home aeroallergen plan runs separately from the in-clinic Vespula VIT an allergist provides for the hornet venom itself.
What European Hornet SCIT Actually Costs
Vespula VIT used for European hornet allergy is covered under standard allergy benefits for documented Hymenoptera sting anaphylaxis. Insurers may require documentation that V. crabro venom is not FDA-licensed in the US and that Vespula is the medically accepted cross-reactive alternative per EAACI guidelines. Prior authorization is typically required for venom extract preparation (CPT 95165). Curex at-home IgE testing identifies specific european hornet sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your european hornet allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
European Hornet SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Vespa crabro is the only true hornet (genus Vespa) established in continental North America. Yellow hornet (Dolichovespula arenaria) and white-faced hornet (Dolichovespula maculata) are Dolichovespula — a different genus in the same Vespidae family — despite their common-name 'hornet' labels. The distinction matters clinically: V. crabro is larger (25–35 mm body length), nests in hollow trees, attics, and barns rather than aerial carton nests, and shows crepuscular/nocturnal foraging behavior that may attract individuals to outdoor lighting — a unique risk pattern not shared by the Dolichovespula species.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.